TEVA-FLURBIPROFEN TABLET
Valsts: Kanāda
Valoda: angļu
Klimata pārmaiņas: Health Canada
Produkta apraksts
(SPC)
14-07-2015
Daži šī produkta dokumenti pašlaik nav pieejami. Varat nosūtīt pieprasījumu mūsu klientu apkalpošanas dienestam, un mēs jums paziņosim, tiklīdz mēs tos varēsim iegūt.
Nosūtīt pieprasījumu.
Nosūtīt pieprasījumu.
Aktīvā sastāvdaļa:
FLURBIPROFEN
Pieejams no:
TEVA CANADA LIMITED
ATĶ kods:
M01AE09
SNN (starptautisko nepatentēto nosaukumu):
FLURBIPROFEN
Deva:
50MG
Zāļu forma:
TABLET
Kompozīcija:
FLURBIPROFEN 50MG
Ievadīšanas:
ORAL
Vienības iepakojumā:
100/500
Receptes veids:
Prescription
Ārstniecības joma:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Produktu pārskats:
Active ingredient group (AIG) number: 0115998002; AHFS:
Autorizācija statuss:
CANCELLED POST MARKET
Autorizācija datums:
2019-08-08
Produkta apraksts
PRODUCT MONOGRAPH
PR
TEVA-FLURBIPROFEN
(Flurbiprofen tablets BP)
50 mg and 100 mg Tablets
Nonsteroidal anti-inflammatory drug (NSAID)
Teva Canada Limited
Date of Revision:
30 Novopharm Court
July 14, 2015
Toronto, Ontario
M1B 2K9
www.tevacanada.com
Control No.: 184835
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
INDICATIONS AND CLINICAL USE
..........................................................................
3
CONTRAINDICATIONS
................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................
5
ADVERSE REACTIONS
...............................................................................................
16
DRUG INTERACTIONS
...............................................................................................
19
DOSAGE AND ADMINISTRATION
..........................................................................
22
OVERDOSAGE
..............................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
....................................................... 23
STORAGE AND
STABILITY.......................................................................................
25
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................... 25
PART II: SCIENTIFIC INFORMATION
..............................................................................
27
PHARMACEUTICAL INFORMATION
.....................................................................
27
CLINICAL TRIALS
.......................................................................................................
28
DETAILED PHARMACOLOGY
.................................................................................
30
TOXICOLOGY
..............................................................................................................
30
REFERENCES
.
Izlasiet visu dokumentu
